AstraZeneca PLC’s Lynparza (olaparib) appears headed for a restricted indication in first-line, metastatic castration-resistant prostate cancer (mCRPC) after a US Food and Drug Administration advisory committee voted overwhelmingly on 28 April to recommend limiting the PARP-inhibitor to patients whose tumors carry the BRCA mutation.
Eleven of 13 members of the Oncologic Drugs Advisory Committee favored an indication restricted by BRCA mutation status – the...